Role of PCSK9 Inhibitors in the Management of Patients with Familial Hypercholesterolemia
June 26, 2019
December 26, 2019
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by National Lipid Association and PlatformQ Health Education, LLC.
Supported by an educational grants from Sanofi US , and Regeneron Pharmaceuticals.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Physician Assistants — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Pharmacists — maximum of 1.0 contact hour(s) (.10 CEUs)
- Nurses — maximum of 1.0 contact hours (includes 0.2 contact hours of pharmacotherapy).
All other health care professionals completing this course will be issued a statement of participation.
This activity is designed to meet the needs of cardiologists, internal medicine physicians, primary care physicians, endocrinologists, physician assistants, nurse practitioners, nurses, and pharmacists.
At the conclusion of this activity, all participants should be able to:
- Recognize the warning signs of Familial Hypercholesterolemia (FH) in patients who present with high cholesterol
- Devise medical treatment plans in line with evidence-based guidelines for LDL-C management in patients with FH
- Outline strategies to address barriers to access for PCSK9 inhibitors for patients with FH with poor control of total cholesterol and LDL-C levels
At the conclusion of all NLA-accredited activities, all participants should be able to:
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team
Christie M. Ballantyne, MD
Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Director, Lipid Metabolism and Atherosclerosis Clinic Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Christopher P. Cannon, MD
Education Director, Cardiovascular Innovation, Cardiology Division
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and PlatformQ Health Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this Internet Enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants Credit Designation Statement
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Pharmacists Designation Statement
Universal Activity Number – JA0007192-9999-19-017-H01-P (Application). This Activity has been approved for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
Nursing Credit Designation
The maximum number of hours awarded for this CE activity is 1.0 contact hours.
For the advanced practice nurse, this activity has 0.2 contact hours of pharmacotherapy content.
Disclosure of Financial Relationships
Christie M. Ballantyne, MD
- Grant/Research Support: Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, ADA, AHA
- Consultant: Abbott Diagnostic, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Christopher P. Cannon, MD
- Grant/Research Support: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck
- Consultant: Aegerion, Alnylam, Amarin, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Eisai, Innovent, Janssen, Kowa, Merck, Pfizer, Regeneron, Sanofi
PlatformQ Health Education, LLC., has nothing to disclose.
NLA, has nothing to disclose.
NLA CME Reviewers
Susan Halli Demeter, DNP, FNP-BC, CLS, FNLA, has nothing to disclose.
Criteria for Success
To participate in the activity, go to www.cardiocarelive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credit(s)™, participants must receive a minimum score of 70% on the posttest.If you have questions about this CME/CE activity, please contact the NLA at email@example.com . Please claim credit by June 26, 2020.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Please contact the National Lipid Association at firstname.lastname@example.org
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting email@example.com with the subject line “Data Request”